Iron Balance and the Role of Hepcidin in Chronic Kidney Disease

被引:123
|
作者
Ganz, Tomas [1 ]
Nemeth, Elizabeta [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, CHS 37-055, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
Anemia; inflammation; iron deficiency; renal failure; REGULATED EIF2-ALPHA KINASE; SERUM HEPCIDIN; MAINTENANCE HEMODIALYSIS; MAMMALIAN IRON; ANEMIA; FERROPORTIN; HOMEOSTASIS; DEFICIENCY; CKD; ERYTHROPOIESIS;
D O I
10.1016/j.semnephrol.2016.02.001
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The hepatic iron-regulatory hormone hepcidin and its receptor, the cellular iron exporter ferroportin, constitute a feedback-regulated mechanism that maintains adequate plasma concentrations of iron-transferrin for erythropoiesis and other functions, ensures sufficient iron stores, and avoids iron toxicity and iron-dependent microbial pathogenesis. In chronic kidney disease, inflammation and impaired renal clearance increase plasma hepcidin, inhibiting duodenal iron absorption and sequestering iron in macrophages. These effects of hepcidin can cause systemic iron deficiency, decreased availability of iron for erythropoiesis, and resistance to endogenous and exogenous erythropoietin. Together with impaired renal production of erythropoietin, hepcidin-mediated iron restriction contributes to anemia of chronic kidney disease. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [1] Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin
    Sarafidis, Pantelis A.
    Rumjon, Adam
    MacLaughlin, Helen L.
    Macdougall, Iain C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (01) : 50 - 57
  • [2] Iron, hepcidin and chronic kidney disease
    Fievet, Patrick
    Brazier, Francois
    NEPHROLOGIE & THERAPEUTIQUE, 2011, 7 (02): : 86 - 91
  • [3] Hepcidin is a Potential Regulator of Iron Status in Chronic Kidney Disease
    Tsuchiya, Ken
    Nitta, Kosaku
    THERAPEUTIC APHERESIS AND DIALYSIS, 2013, 17 (01) : 1 - 8
  • [4] Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
    Ueda, Norishi
    Takasawa, Kazuya
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (14) : 1417 - 1452
  • [5] The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease
    Mercadel, Lucile
    Metzger, Marie
    Haymann, Jean Philippe
    Thervet, Eric
    Boffa, Jean-Jacques
    Flamant, Martin
    Vrtovsnik, Francois
    Houillier, Pascal
    Froissart, Marc
    Stengel, Benedicte
    PLOS ONE, 2014, 9 (06):
  • [6] Hepcidin-A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease
    Zaritsky, Joshua
    Young, Brian
    Wang, He-Jing
    Westerman, Mark
    Olbina, Gordana
    Nemeth, Elizabeta
    Ganz, Tomas
    Rivera, Seth
    Nissenson, Allen R.
    Salusky, Isidro B.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (06): : 1051 - 1056
  • [7] Hepcidin and iron metabolism disorders in patients with chronic kidney disease
    Jefic, Marija
    Cvetkovic, Tatjana
    Djordjevic, Vidojko
    Damnjanovic, Goran
    Vlahovic, Predrag
    Kocic, Gordana
    Djindjic, Natasa
    Jovovic, Biljana
    Antic, Ana
    VOJNOSANITETSKI PREGLED, 2013, 70 (04) : 368 - 373
  • [8] Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis
    Antunes, Sandra A.
    Vilela, Rosana Q.
    Vaz, Jose D.
    Canziani, Maria Eugenia F.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2014, 37 (07) : 521 - 528
  • [9] Hepcidin and Iron in Health and Disease
    Nemeth, Elizabeta
    Ganz, Tomas
    ANNUAL REVIEW OF MEDICINE, 2023, 74 : 261 - 277
  • [10] The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease
    Hamano, Hirofumi
    Ikeda, Yasumasa
    Watanabe, Hiroaki
    Horinouchi, Yuya
    Izawa-Ishizawa, Yuki
    Imanishi, Masaki
    Zamami, Yoshito
    Takechi, Kenshi
    Miyamoto, Licht
    Ishizawa, Keisuke
    Tsuchiya, Koichiro
    Tamaki, Toshiaki
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 (04) : 586 - 597